Institute of Cancer Research: Trial Shows Benefits of Targeted Drug Against Early-Stage Breast Cancer With Inherited BRCA Mutation
June 04, 2021
June 04, 2021
LONDON, England, June 4 (TNSRes) -- The Institute of Cancer Research issued the following news release:
Women with high-risk, early-stage breast cancer who also have inherited faults in their BRCA1 or BRCA2 genes have shown a remarkable response to the targeted drug olaparib in a major clinical trial.
The OlympiA trial showed that adding olaparib for one year following standard treatment for patients who had an inherited BRCA mutation and early-stage, HER-2 negative bre . . .
Women with high-risk, early-stage breast cancer who also have inherited faults in their BRCA1 or BRCA2 genes have shown a remarkable response to the targeted drug olaparib in a major clinical trial.
The OlympiA trial showed that adding olaparib for one year following standard treatment for patients who had an inherited BRCA mutation and early-stage, HER-2 negative bre . . .